DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES

• Main Authors: LI CHIUNG, KAPIL GADKAR, IRAJ HOSSEINI, SAROJA RAMANUJAN, CHU YU-WAYE
• Format: Patent
• Language: English; Japanese
• Published: 30.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide a method of treating a human patient having a B cell proliferative disorder using anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.SOLUTION: A method of treating a subject having a B cell proliferative disorder comprises administering to the subject a bispecific antibody that binds to CD20 and CD3 in a dosing regimen having at least a first dosing cycle and a second dosing cycle, where: (a) the first dosing cycle has a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of the bispecific antibody, where the C1D1 and the C1D2 are each not greater than the C1D3; and (b) the second dosing cycle has a single dose (C2D1) of the bispecific antibody, where the C2D1 is equal to or greater than the C1D3.SELECTED DRAWING: None 【課題】抗表面抗原分類２０（ＣＤ２０）／抗表面抗原分類３（ＣＤ３）の二重特異性抗体を使用する、Ｂ細胞増殖性疾患を有するヒト患者の治療方法を提供する。【解決手段】Ｂ細胞増殖性疾患を有する被検体を処置する方法であって、少なくとも第一投与サイクル及び第二投与サイクルを有する投与計画においてＣＤ２０及びＣＤ３に結合する二重特異性抗体を前記被検体へ投与することを備え、（ａ）第一投与サイクルは二重特異性抗体の第一投与量（Ｃ１Ｄ１）、第二投与量（Ｃ１Ｄ２）、及び第三投与量（Ｃ１Ｄ３）を有し、Ｃ１Ｄ１及びＣ１Ｄ２はＣ１Ｄ３より各多くなく、（ｂ）第二投与サイクルは二重特異性抗体の単回投与量（Ｃ２Ｄ１）を有し、Ｃ２Ｄ１はＣ１Ｄ３以上である、前記方法とする。【選択図】なし